SI-BONE Inc. (NASDAQ:SIBN) is a leading medical device company specializing in minimally invasive surgical implants for the sacroiliac joint. Known for its innovative iFuse Implant System, SI-BONE competes in the orthopedic sector, focusing on solutions for joint-related issues.
On August 11, 2025, Cantor Fitzgerald reiterated its "Overweight" rating for SI-BONE Inc. (NASDAQ:SIBN), indicating confidence in the company's growth potential. At the time, the stock was priced at $15.68. This rating suggests that Cantor Fitzgerald believes SIBN will outperform the average market return, encouraging investors to hold the stock.
SI-BONE's financial performance in the second quarter of 2025 supports this positive outlook. The company reported a worldwide revenue growth of 21.7%, reaching $48.6 million. U.S. revenue saw a 22.8% increase, totaling $46.4 million. These figures highlight the company's strong market presence and ability to expand its revenue base.
The company's operational improvements are also noteworthy. SI-BONE achieved a positive adjusted EBITDA and reached a cash flow breakeven point, indicating financial stability. The gross margin improved by 80 basis points to 79.8%, and the net loss was reduced by 31.2% to $6.2 million. These metrics reflect effective cost management and operational efficiency.
SI-BONE's strategic initiatives are further bolstered by regulatory support. The Centers for Medicare & Medicaid Services (CMS) confirmed the New Technology Add-On Payment (NTAP) for procedures involving iFuse TORQ TNT, effective October 1, 2025. This will provide an additional payment of up to $4,136, enhancing the company's revenue potential. Additionally, CMS proposed the continuation of the Transitional Pass-Through Payment for Granite, further supporting SI-BONE's financial prospects.
